GMP Xynapse™-T Reagents for Functional Characterization of TCR-Engineered T Cells to Support T-knife Therapeutics’ Clinical Trial
Immudex Advances into the Clinical Space with Xynapse™-T for functional characterization of TCR-Engineered T Cells
Copenhagen, Denmark — March 10, 2026 — Immudex today announced that it will supply GMP-grade Xynapse™-T reagents to support T-knife Therapeutics in the functional characterization and streamlined potency testing of TCR-engineered T cells as part of their clinical development program.
Xynapse™-T is Immudex’s non-cellular, antigen-presenting platform designed to deliver antigen-specific T cell stimulation through a defined combination of peptide–MHC complexes and costimulatory signaling. The availability of GMP-compatible Xynapse™-T reagents provides an easy-to-use, consistent, and scalable alternative to antigen-presenting cells, supporting reproducible assay performance and streamlined regulatory compliance.
“T-cell therapies require reliable analytical tools, and we are pleased that our Xynapse™-T technology will support T-knife in advancing their innovative TCR-T program,” said Liselotte Brix, CSO, Immudex.
About Immudex
Immudex is a global leader in precision immune monitoring and advanced T cell characterization technologies. Our product portfolio, including Dextramer®, dCODE, and Xynapse™ platforms, supports basic research, translational studies, and cell therapy development by enabling highly specific detection, activation, and analysis of antigen-specific T cells. Find out more at www.immudex.com.